STAT+: Key senators eye new, more ambitious legislation to lower insulin prices
WASHINGTON — Key Senate lawmakers have begun writing a bipartisan bill that would cap the prices…
Category: Congress
STAT+: Lawmakers and a Pelosi aide turn lobbyist to push for new health agency’s independence
WASHINGTON — Health secretary Xavier Becerra is suddenly the target of a frenzied lobbying campaign…
NIH’s identity crisis: The pandemic and the search for a new leader leave the agency at a crossroads
WASHINGTON — Under the reign of Francis Collins, the National Institutes of Health was untouchable….
Before Aduhelm, Billy Dunn was a superstar at the FDA
You’re reading the web edition of D.C. Diagnosis, STAT’s weekly newsletter about the politics and…
STAT+: An ALS therapy sets up a crucial test of the FDA’s independence
WASHINGTON — A high-profile, experimental therapy for ALS is teeing up a crucial test of…
Listen: Doing biotech in Ukraine, drug pricing déjà vu, & Covid surges overseas
How should pharma treat Russia? Why can’t Congress pass a drug pricing bill? And what…
STAT+: Lawmakers face off about the future of the FDA’s accelerated approval pathway
WASHINGTON – Lawmakers are facing off over the future of the Food and Drug Administration’s…
Medicare premiums could decrease ‘soon,’ after decision on Alzheimer’s drug Aduhelm
WASHINGTON — Whether seniors get an unprecedented mid-year discount on Medicare premiums will hinge on…
STAT+: Biden’s agency to ‘end cancer as we know it’ is finally real. But it has a chaotic road ahead
WASHINGTON — Congress has finally funded the agency that President Biden has pledged will help…
Inside the push for a permanent pandemic preparedness office at the White House
You’re reading the web edition of D.C. Diagnosis, STAT’s weekly newsletter about the politics and…
White House begs Congress for Covid funding amid concern about Omicron sister variant
WASHINGTON — The White House is begging Congress for more funds to help with Covid-19 surveillance,…
STAT+: Three years after the Senate grilled drug makers … nothing’s changed
WASHINGTON – Back in 2019, when the Senate Finance Committee called seven drug industry executives…
STAT+: In New York appearance, CMS administrator pushes for Congress to act on drug prices
NEW YORK — When Chiquita Brooks-LaSure, the Biden official who oversees the Medicare and Medicaid health…
‘Haven’t we learned anything?’: Experts warn of disastrous consequences if pandemic funding dries up
WASHINGTON — The failure of Congress this week to approve additional pandemic response funding could…
Nurses, more powerful and visible after Covid, capitalize on new clout in Washington
WASHINGTON — Since the start of Covid-19, nurses have been hailed as heroes. But two…
STAT+: Congress moves toward giving FDA authority over synthetic nicotine products like Puff Bar
WASHINGTON — Lawmakers are within striking distance of closing the largest loophole in the Food…
STAT+: Congress considers a longer phase-out of looser, Covid-era telehealth policies
WASHINGTON — Lawmakers are considering extending the more flexible telehealth policies put in place during the…
Covid budget crunch looms over government funding fight
You’re reading the web edition of D.C. Diagnosis, STAT’s weekly newsletter about the politics and…
STAT+: A glaring gap in Congress’ surprise billing law leaves patients on the hook for pricey, out-of-network lab tests
For Soung Luy, it seemed easy: His primary care doctor told him he needed blood…
STAT+: Key Democrat moves to crack down on FDA accelerated approvals
WASHINGTON – A powerful Democratic lawmaker has introduced a bill that would dramatically rein in…
.jpg)
Doctors, companies push to keep looser, pandemic-era rules for prescribing opioid addiction treatment via telemedicine
WASHINGTON — It got a lot easier for patients with opioid addiction to get their…
White House transparency disputes imperil funds to buy Covid therapeutics
WASHINGTON — The White House hasn’t publicly detailed exactly how it’s spent the more than…
In State of the Union, Biden walks a fine line on Covid optimism
WASHINGTON — President Biden on Tuesday vowed that the U.S. won’t become complacent in its…
The FDA’s promised menthol ban is about to face a critical test
You’re reading the web edition of D.C. Diagnosis, STAT’s weekly newsletter about the politics and…
Opinion: Recognizing obesity as a disease, not a choice, is a step toward health equity
When the American Medical Association recognized obesity as a disease in 2013, doctors and other…
STAT+: 3 challenges for hospitals in 2022
WASHINGTON — Hospitals didn’t get the relief the rollout of Covid-19 vaccines seemed to promise at…
Califf sails through confirmation hearing for FDA job, despite tensions over opioids
WASHINGTON — Robert Califf escaped largely unscathed from a two-hour hearing Tuesday vetting him to…
STAT+: Hospitals just dodged a bullet in Democrats’ major spending package. Can they sidestep a bigger one?
WASHINGTON — Hospitals and their lobbyists in Washington just wriggled their way out of a…
STAT+: Hospital, physician lobbies sue Biden administration over surprise billing regulation
WASHINGTON — The nation’s largest hospital and physician lobbying groups are suing the Biden administration…
STAT+: Hospitals and doctors fail to stop end-of-year Medicare cuts, for now
WASHINGTON — Hospitals and physicians lost a lobbying battle to stave off Medicare cuts of…
7 policies in Biden’s spending plan aimed at health equity
WASHINGTON — Democrats have made big promises to tackle racial inequities across society, including in…
What does the Build Back Better Act actually mean for the health care industry?
You’re reading the web edition of D.C. Diagnosis, STAT’s weekly newsletter about the politics and…
Democrats’ major drug pricing reforms clear a hurdle in the House
WASHINGTON — House Democrats Friday broke a monthslong logjam and advanced prescription drug pricing reform…
STAT+: Former DARPA director: Biden’s new science agency should be independent, not an NIH office
WASHINGTON — The former director of DARPA, the Pentagon’s high-stakes research arm, says that for…
Moderate Democrats are still seeking changes to the party’s drug pricing package
WASHINGTON — Rep. Kurt Schrader, the Oregon Democrat who has played an outsized role in…
Opinion: People in states without Medicaid expansion can’t wait any longer to build back better
Lawmakers are in the midst of deliberations over the Build Back Better Act, a landmark…
Opinion: Drug pricing bill’s unintended consequences will distort drug development
After months of wrangling, Democratic lawmakers have agreed on a drug pricing bill. The House…
How Nancy Pelosi almost killed drug pricing reform
WASHINGTON — The White House stunned health care experts last month when it declared it was…
Here’s who wins and loses in Democrats’ new prescription drug pricing deal
WASHINGTON — Congressional Democrats on Tuesday announced they had agreed to a broad plan to overhaul…
Democrats circulate a new drug pricing outline with a big carveout for small biotechs
WASHINGTON — A proposed version of drug pricing legislation circulating among Capitol Hill aides and…
Opinion: I’ve worked with Robert Califf. He is the leader the FDA needs
If the cascade of news reports are true, President Biden is finally about to name…
.jpg)
Here’s where Democrats’ resurrected drug pricing talks are headed
You’re reading the web edition of D.C. Diagnosis, STAT’s weekly newsletter about the politics and…
STAT+: Could Robert Califf’s ties to tech complicate his FDA nomination?
WASHINGTON — Robert Califf spent his first confirmation hearing explaining his entanglements with the drug…
STAT+: Here’s how Biden can address high drug prices, without help from Congress
WASHINGTON — If President Biden wants major pharmaceutical industry reforms, he may have to achieve…
Pelosi working to gather support for last-minute, last-ditch drug pricing policy
WASHINGTON — House Speaker Nancy Pelosi’s office is working to gather support for a last-ditch…
STAT+: Biden abandons his push to lower drug prices
WASHINGTON — The White House is abandoning every single policy idea aimed at lowering prescription…
STAT+: Democratic senators raise concerns with potential FDA pick
WASHINGTON — Sens. Joe Manchin and Richard Blumenthal have concerns with President Biden’s rumored nominee…
Which drug maker spent the most on lobbying this summer? The answer will surprise you
You’re reading the web edition of D.C. Diagnosis, STAT’s weekly newsletter about the politics and…
Congress has bipartisan support to try to deal with the next pandemic. But those talks are already falling behind
WASHINGTON — Addressing the federal government’s failures during the Covid-19 pandemic has fallen off the…
STAT+: The four senators who could make or break Democrats’ drug pricing ambitions
WASHINGTON — The fate of the Democratic party’s ambitious goal of allowing Medicare to negotiate…